Zacks Research Issues Positive Estimate for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Analysts at Zacks Research raised their Q1 2025 earnings per share estimates for Bausch Health Companies in a research report issued on Monday, January 20th. Zacks Research analyst R. Department now expects that the company will earn $0.87 per share for the quarter, up from their prior forecast of $0.85. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2025 earnings at $1.04 EPS, Q4 2025 earnings at $1.17 EPS, Q1 2026 earnings at $1.10 EPS, Q2 2026 earnings at $1.15 EPS and Q3 2026 earnings at $1.38 EPS.

A number of other equities research analysts have also issued reports on BHC. Royal Bank of Canada increased their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Finally, StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Stock Performance

Shares of BHC opened at $7.73 on Wednesday. The company’s 50-day simple moving average is $7.86 and its 200-day simple moving average is $7.45. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The stock has a market capitalization of $2.79 billion, a PE ratio of -16.09 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The firm had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the prior year, the company earned $1.03 EPS. Bausch Health Companies’s revenue was up 12.2% on a year-over-year basis.

Institutional Trading of Bausch Health Companies

A number of hedge funds and other institutional investors have recently bought and sold shares of BHC. DGS Capital Management LLC purchased a new position in shares of Bausch Health Companies in the 4th quarter valued at about $143,000. SG Americas Securities LLC boosted its holdings in Bausch Health Companies by 62.0% in the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after purchasing an additional 1,263,706 shares in the last quarter. Merit Financial Group LLC purchased a new position in Bausch Health Companies in the fourth quarter valued at approximately $228,000. Sanders Morris Harris LLC raised its holdings in Bausch Health Companies by 16.0% during the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock worth $234,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Range Financial Group LLC purchased a new stake in shares of Bausch Health Companies during the 4th quarter worth approximately $1,004,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.